Inactive Instrument

News Aquinox Pharmaceuticals Inc Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
-	-

27/06	BMO Initiates Neurogene at Outperform With $65 Price Target	MT
18/06	Neurogene Doses First Patient in High-Dose Group of Rett Syndrome Trial	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BMO Initiates Neurogene at Outperform With $65 Price Target	27/06	MT
Neurogene : Corporate Presentation June 2024	21/06	PU
Neurogene Doses First Patient in High-Dose Group of Rett Syndrome Trial	18/06	MT
Neurogene : IRSF Clinical Safety Poster	18/06	PU
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome	18/06	BU
Neurogene Inc. Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome	18/06	CI
Baird Initiates Neurogene With Outperform Rating, $54 Price Target	11/06	MT
Neurogene to Participate in Upcoming Conferences	05/06	BU
Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program	03/06	MT
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program	03/06	BU
Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program	03/06	CI
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	13/05	AQ
Neurogene: Q1 Earnings Snapshot	10/05	AQ
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	10/05	BU
Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Neurogene : ASGCT NGN-401 Clinical Safety Poster	07/05	PU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting	07/05	BU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	07/05	CI
Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	29/04	MT
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	23/04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aquinox Pharmaceuticals Inc Nasdaq

Equities

Summary

Filters